134 related articles for article (PubMed ID: 37259738)
1. Salvage camrelizumab for an intractable NK/T cell lymphoma patient with two instances of intestinal perforation: a case report and literature review.
Xia Y; Li QH; Liu T; Liu XX; Pan HX; Zhang LL; Zhu F
Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4570-4577. PubMed ID: 37259738
[TBL] [Abstract][Full Text] [Related]
2. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell Lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.
Lai J; Xu P; Jiang X; Zhou S; Liu A
BMC Cancer; 2017 Jul; 17(1):507. PubMed ID: 28754096
[TBL] [Abstract][Full Text] [Related]
4. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
[TBL] [Abstract][Full Text] [Related]
5. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
6. Perforation in an intestinal malignant lymphoma case.
Imataki O; Shiroshita K; Uchida S; Kida J; Akamoto S; Uemura M
BMC Res Notes; 2016 Jun; 9():308. PubMed ID: 27297406
[TBL] [Abstract][Full Text] [Related]
7. Aggressive natural killer/T-cell lymphoma masquerading as acute orbital hemorrhage: a case report.
Zhang J; Chen H; Lin W; Wu Z
Int J Clin Exp Pathol; 2020; 13(5):1081-1085. PubMed ID: 32509082
[TBL] [Abstract][Full Text] [Related]
8. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
9. Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.
Liu TZ; Zheng YJ; Zhang ZW; Li SS; Chen JT; Peng AH; Huang RW
World J Clin Cases; 2020 Apr; 8(7):1278-1286. PubMed ID: 32337203
[TBL] [Abstract][Full Text] [Related]
10. Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.
Zhu F; Li Q; Pan H; Xiao Y; Liu T; Liu X; Li J; Wu G; Zhang L
Front Oncol; 2020; 10():1725. PubMed ID: 32984055
[TBL] [Abstract][Full Text] [Related]
11. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
Wang C; Liu Y; Dong L; Li X; Yang Q; Brock MV; Mei Q; Liu J; Chen M; Shi F; Liu M; Nie J; Han W
Clin Cancer Res; 2021 May; 27(10):2782-2791. PubMed ID: 33674274
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of PD-1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study.
Tian J; Hao M; Liu Q; Xiao F; Li Y; Qi M; Gao J; Liu L; Yin D
Hematol Oncol; 2023 Aug; 41(3):396-406. PubMed ID: 36516297
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center.
Gale J; Simmonds PD; Mead GM; Sweetenham JW; Wright DH
J Clin Oncol; 2000 Feb; 18(4):795-803. PubMed ID: 10673521
[TBL] [Abstract][Full Text] [Related]
17. Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report.
Suzuki T; Iwamoto K; Nozaki R; Saiki Y; Tanaka M; Fukunaga M; Yamada K
BMC Surg; 2021 Jan; 21(1):50. PubMed ID: 33478454
[TBL] [Abstract][Full Text] [Related]
18. An aggressive primary orbital natural killer/T-cell lymphoma case: poor response to chemotherapy.
Marchino T; Ibáñez N; Prieto S; Novelli S; Szafranska J; Mozos A; Graell X; Buil JA
Ophthalmic Plast Reconstr Surg; 2014; 30(5):e131-4. PubMed ID: 24317101
[TBL] [Abstract][Full Text] [Related]
19. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
20. Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma.
Hu Y; Chen M; Song Y; Liu X; Gou F; Zhang J; Huang Y
Am J Clin Oncol; 2020 Apr; 43(4):257-262. PubMed ID: 31764026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
